Edison Investment Research - Collplant Holdings Ltd (CLGN) CollPlant Holdings - Ongoing third-party interest in BioInk

Report

Edison Investment Research

Maxim Jacobs

CollPlant Holdings - Ongoing third-party interest in BioInk

CollPlant demonstrated another productive quarter with a 209% increase in reported revenue over the same period in 2017, mainly attributed to sales of its BioInk product in the US and its Vergenix product brands, primarily its VergenixSTR for tendinopathy, in Europe. The rhCollagen-based BioInk continues to demonstrate that it is a strategic area of development for CollPlant with repeat sales to third parties.

03/10/2018 4 EN

Underlying

Collplant Holdings Ltd

CollPlant Holdings is a biotechnology medical device company based in Israel. Co. is focused on advancing regenerative medicine by utilizing its proprietary processing technologies for human collagen and other recombinant proteins. Co. is engaged in developing a substantial range of biomaterials-based products applicable in multiple medical markets, including orthopaedics, wound management, cardiology and general surgery. In addition to virgin collagen, Co. also developes a family of products that offers a range of scaffolds. including sheets, sponges, gels, meshes, microsphere and compounds. Co. also plans to offer solutions for soft and hard tissue repair in diverse applications.

See profile

IL0004960188 Israel

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Maxim Jacobs

Other Reports on these Companies

Edison Investment Research

CollPlant Holdings - Enters into licensing and commercialisation agreement

In late October 2018, CollPlant and United Therapeutics (NASDAQ: UTHR) announced a licensing, development and commercialisation agreement for 3D bioprinted lung transplants using rhCollagen-based BioInk. This news follows the United Therapeuticsâ€™ Science Day in September, where its founder and CEO presented the companyâ€™s R&D using CollPlantâ€™s rhCollagen to 3D bioprint lung scaffolds. This co-development agreement further validates CollPlantâ€™s technology.

October 29, 2018 October 29, 2018 5 EN

Edison Investment Research

CollPlant Holdings - A productive year to date

The year to date has been highly productive for CollPlant. It has completed a new production facility in Rehovot to support its increased commercial efforts. These include both its BioInk product for 3D bioprinting of organs and tissue, as well as VergenixFG and VergenixSTR for wound care and tendinopathy respectively, which are expanding operations in Europe. In addition, the company has announced its intention to de-list from TASE to trade exclusively on NASDAQ.

May 30, 2018 May 30, 2018 4 EN

Sylvania Platinum - Annual guidance maintained, despite strike

Sylvania has maintained annual production guidance despite Q324 results being affected by a 22-day strike, resulting in 10% lower production. The PGM basket price was stable during the quarter, with positive platinum momentum offset by palladium weakness and rhodium prices stable. Operating costs increased by 5.6%, in line with expectations. FY24 production guidance is for 75,000–76,000oz, despite the challenges in Q324. Our PGM outlook is unchanged from our moderated forecasts earlier in the year. We have cut our FY24 EPS forecast by 2.2% from 7.4p to 7.2p on the Q324 miss, but have lifted ou...

May 3, 2024 May 3, 2024 1 EN

Richard Williamson

Richard Williamson

1Spatial - Investing in the transformational SaaS opportunity

1Spatial’s FY24 results reflected robust momentum for the enterprise business and continued improvement in the revenue mix, with investment in growth suppressing margin and cash generation. This investment phase will continue in FY25 to lay the foundation for transformational growth from 1Streetworks and in the US in the coming years. Our scenario analysis indicates the upside from successful execution is significant, with further wins for 1Streetworks and in the US being the key catalysts for more rapid, operationally geared growth to be priced in.

May 3, 2024 May 3, 2024 1 EN

Richard Williamson

Richard Williamson

Datatec - FY24 underlying EPS more than doubles y-o-y

In a second more detailed trading update for FY24, Datatec confirmed revenue growth of 6% to $5.46bn, with Westcon International delivering excellent performance, Logicalis International having a strong H2 and Logicalis Latin America affected by difficult market conditions in Argentina and Brazil. The company also provided provisional EPS data, with reported EPS likely to come in ahead of our forecast and underlying EPS just below our forecast. We maintain our forecasts pending FY24 results on or around 27 May.

May 2, 2024 May 2, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CollPlant Holdings - Ongoing third-party interest in BioInk

CollPlant Holdings - Enters into licensing and commercialisation agreement

CollPlant Holdings - A productive year to date

Sylvania Platinum - Annual guidance maintained, despite strike

1Spatial - Investing in the transformational SaaS opportunity

Datatec - FY24 underlying EPS more than doubles y-o-y

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe